Adjuvant and Neoadjuvant Therapy for Colorectal Cancer

Steven R. Alberts(North Central Cancer Treatment Group), Robert C. Miller(Mayo Clinic), Christopher L. Hallemeier(Mayo Clinic in Arizona), Jason A. Call
Elsevier eBooks
January 1, 2013
10.1016/b978-1-4377-2206-2.00175-5
Cited by 0

Related Papers

Bevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Study E3200
|Journal of Clinical Oncology|2007|2.3k
Cholangiocarcinoma — evolving concepts and therapeutic strategies
|Nature Reviews Clinical Oncology|2017|1.7k
Oxaliplatin, Fluorouracil, and Leucovorin for Patients With Unresectable Liver-Only Metastases From Colorectal Cancer: A North Central Cancer Treatment Group Phase II Study
|Journal of Clinical Oncology|2005|541
Factors Predicting Response, Perioperative Outcomes, and Survival Following Total Neoadjuvant Therapy for Borderline/Locally Advanced Pancreatic Cancer
|Annals of Surgery|2019|445
High-dose bevacizumab improves survival when combined with FOLFOX4 in previously treated advanced colorectal cancer: Results from the Eastern Cooperative Oncology Group (ECOG) study E3200
|Journal of Clinical Oncology|2005|344